Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 consolidation therapy for locally advanced nasopharyngeal carcinoma
ChiCTR1800015670Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegafur in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: No disease progression survival, Lymph node recurrence-free survival rate and 2 more. Started Mar 2018; status: recruiting.
02
Drugs
tegafur
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800015670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015670.